Swedish Orphan Biovitrum AB (publ) (SOBI) - Net Assets

Latest as of March 2026: Skr40.38 Billion SEK ≈ $4.35 Billion USD

Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) has net assets worth Skr40.38 Billion SEK (≈ $4.35 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr81.26 Billion ≈ $8.74 Billion USD) and total liabilities (Skr40.87 Billion ≈ $4.40 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Swedish Orphan Biovitrum AB (publ)'s equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr40.38 Billion
% of Total Assets	49.7%
Annual Growth Rate	14.35%
5-Year Change	62.58%
10-Year Change	604.54%
Growth Volatility	47.89

Swedish Orphan Biovitrum AB (publ) - Net Assets Trend (2002–2025)

This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s net assets have evolved over time, based on quarterly financial data. See SOBI cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Swedish Orphan Biovitrum AB (publ) (2002–2025)

The table below shows the annual net assets of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025. For live valuation and market cap data, see SOBI market cap.

Year	Net Assets	Change
2025-12-31	Skr37.72 Billion ≈ $4.06 Billion	-6.38%
2024-12-31	Skr40.30 Billion ≈ $4.34 Billion	+18.98%
2023-12-31	Skr33.87 Billion ≈ $3.64 Billion	+27.68%
2022-12-31	Skr26.52 Billion ≈ $2.85 Billion	+14.32%
2021-12-31	Skr23.20 Billion ≈ $2.50 Billion	+14.83%
2020-12-31	Skr20.21 Billion ≈ $2.17 Billion	+19.35%
2019-12-31	Skr16.93 Billion ≈ $1.82 Billion	+87.28%
2018-12-31	Skr9.04 Billion ≈ $972.86 Million	+34.92%
2017-12-31	Skr6.70 Billion ≈ $721.08 Million	+25.14%
2016-12-31	Skr5.35 Billion ≈ $576.21 Million	+14.18%
2015-12-31	Skr4.69 Billion ≈ $504.65 Million	+3.68%
2014-12-31	Skr4.52 Billion ≈ $486.73 Million	-5.17%
2013-12-31	Skr4.77 Billion ≈ $513.25 Million	-1.42%
2012-12-31	Skr4.84 Billion ≈ $520.65 Million	-2.53%
2011-12-31	Skr4.96 Billion ≈ $534.14 Million	+14.30%
2010-12-31	Skr4.34 Billion ≈ $467.31 Million	+220.99%
2009-12-31	Skr1.35 Billion ≈ $145.58 Million	+5.28%
2008-12-31	Skr1.28 Billion ≈ $138.28 Million	-11.55%
2007-12-31	Skr1.45 Billion ≈ $156.34 Million	+5.14%
2006-12-31	Skr1.38 Billion ≈ $148.70 Million	-19.08%
2005-12-31	Skr1.71 Billion ≈ $183.77 Million	-17.73%
2004-12-31	Skr2.08 Billion ≈ $223.37 Million	-0.98%
2003-12-31	Skr2.10 Billion ≈ $225.57 Million	+21.45%
2002-12-31	Skr1.73 Billion ≈ $185.73 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Swedish Orphan Biovitrum AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2243784500000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	Skr22.40 Billion	59.39%
Common Stock	Skr196.00 Million	0.52%
Other Components	Skr15.12 Billion	40.09%
Total Equity	Skr37.72 Billion	100.00%

Swedish Orphan Biovitrum AB (publ) Competitors by Market Cap

The table below lists competitors of Swedish Orphan Biovitrum AB (publ) ranked by their market capitalization.

Company	Market Cap
Sprott Physical Gold Trust TO:PHYS	$16.20 Billion
Atlassian Corp Plc NASDAQ:TEAM	$16.21 Billion
Jiangxi Ganfeng Lithium Co Ltd SHE:002460	$16.24 Billion
Joint Stock Company Kaspi.kz NASDAQ:KSPI	$16.26 Billion
Evergreen Marine Corp Taiwan Ltd TW:2603	$16.17 Billion
JIO Financial Services Ltd NSE:JIOFIN	$16.15 Billion
PTC Inc NASDAQ:PTC	$16.14 Billion
Banco de Sabadell S.A MC:SAB	$16.13 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Swedish Orphan Biovitrum AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 40,286,000,000 to 37,717,000,000, a change of -2,569,000,000 (-6.4%).
Net income of 478,000,000 contributed positively to equity growth.
Share repurchases of 245,000,000 reduced equity.
New share issuances of 245,000,000 increased equity.
Other comprehensive income decreased equity by 981,000,000.
Other factors decreased equity by 2,066,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr478.00 Million	+1.27%
Share Repurchases	Skr245.00 Million	-0.65%
Share Issuances	Skr245.00 Million	+0.65%
Other Comprehensive Income	Skr-981.00 Million	-2.6%
Other Changes	Skr-2.07 Billion	-5.48%
Total Change	Skr-	-6.38%

Book Value vs Market Value Analysis

This analysis compares Swedish Orphan Biovitrum AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.01x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 25.66x to 4.01x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	Skr16.95	Skr435.00	x
2003-12-31	Skr20.59	Skr435.00	x
2004-12-31	Skr20.38	Skr435.00	x
2005-12-31	Skr16.77	Skr435.00	x
2006-12-31	Skr12.42	Skr435.00	x
2007-12-31	Skr13.90	Skr435.00	x
2008-12-31	Skr11.48	Skr435.00	x
2009-12-31	Skr23.75	Skr435.00	x
2010-12-31	Skr21.78	Skr435.00	x
2011-12-31	Skr20.50	Skr435.00	x
2012-12-31	Skr18.24	Skr435.00	x
2013-12-31	Skr17.98	Skr435.00	x
2014-12-31	Skr16.99	Skr435.00	x
2015-12-31	Skr17.54	Skr435.00	x
2016-12-31	Skr19.89	Skr435.00	x
2017-12-31	Skr24.82	Skr435.00	x
2018-12-31	Skr33.41	Skr435.00	x
2019-12-31	Skr54.90	Skr435.00	x
2020-12-31	Skr64.84	Skr435.00	x
2021-12-31	Skr74.67	Skr435.00	x
2022-12-31	Skr84.89	Skr435.00	x
2023-12-31	Skr103.90	Skr435.00	x
2024-12-31	Skr116.58	Skr435.00	x
2025-12-31	Skr108.50	Skr435.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Swedish Orphan Biovitrum AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.27%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.69%
• Asset Turnover: 0.42x
• Equity Multiplier: 1.79x
Recent ROE (1.27%) is below the historical average (5.69%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	-2.08%	-2.75%	0.65x	1.15x	Skr-208.43 Million
2003	17.64%	22.31%	0.70x	1.13x	Skr160.12 Million
2004	-1.28%	-4.11%	0.27x	1.17x	Skr-234.05 Million
2005	10.32%	18.81%	0.34x	1.60x	Skr5.45 Million
2006	6.71%	7.72%	0.58x	1.50x	Skr-45.51 Million
2007	5.44%	6.29%	0.64x	1.34x	Skr-66.30 Million
2008	-26.10%	-29.40%	0.44x	2.01x	Skr-463.86 Million
2009	2.40%	2.50%	0.46x	2.07x	Skr-102.84 Million
2010	-2.40%	-5.48%	0.27x	1.63x	Skr-538.64 Million
2011	0.36%	0.94%	0.29x	1.35x	Skr-478.42 Million
2012	-2.09%	-5.25%	0.30x	1.31x	Skr-584.68 Million
2013	-1.95%	-4.27%	0.33x	1.37x	Skr-569.88 Million
2014	-5.92%	-10.27%	0.41x	1.41x	Skr-720.12 Million
2015	1.46%	2.12%	0.39x	1.77x	Skr-400.54 Million
2016	15.11%	15.55%	0.52x	1.86x	Skr273.64 Million
2017	17.14%	17.64%	0.60x	1.63x	Skr478.56 Million
2018	26.75%	26.46%	0.53x	1.90x	Skr1.51 Billion
2019	19.52%	23.19%	0.31x	2.70x	Skr1.61 Billion
2020	16.06%	21.26%	0.32x	2.39x	Skr1.22 Billion
2021	11.55%	17.25%	0.32x	2.10x	Skr358.70 Million
2022	9.95%	14.04%	0.36x	1.98x	Skr-14.50 Million
2023	7.11%	10.89%	0.30x	2.19x	Skr-977.70 Million
2024	9.64%	14.93%	0.34x	1.87x	Skr-143.60 Million
2025	1.27%	1.69%	0.42x	1.79x	Skr-3.29 Billion

Industry Comparison

This section compares Swedish Orphan Biovitrum AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $299,067,132
Average return on equity (ROE) among peers: -33.20%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Swedish Orphan Biovitrum AB (publ) (SOBI)	Skr40.38 Billion	-2.08%	1.01x	$16.19 Billion
BioGaia AB (publ) (BIOG-B)	$1.88 Billion	10.45%	0.13x	$1.30 Billion
Enzymatica publ AB (ENZY)	$124.97 Million	-36.32%	0.26x	$69.22 Million
Enorama Pharma AB (ERMA)	$7.36 Million	-118.94%	1.10x	$3.07 Million
Gabather AB (publ) (GABA)	$-863.00K	0.00%	0.00x	$1.96 Million
Klaria Pharma Holding AB (KLAR)	$41.13 Million	-86.99%	0.77x	$20.91 Million
Moberg Pharma AB (publ) (MOB)	$178.23 Million	20.09%	0.58x	$50.33 Million
Nanexa AB (NANEXA)	$95.83 Million	-79.72%	0.38x	$86.70 Million
Newbury Pharmaceuticals AB (NEWBRY)	$38.47 Million	-14.45%	0.11x	$7.46 Million
Orexo AB (ORX)	$329.10 Million	7.05%	2.05x	$73.41 Million

About Swedish Orphan Biovitrum AB (publ)

ST:SOBI Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$16.19 Billion

Skr150.44 Billion SEK

Market Cap Rank

#1532 Global

#22 in Sweden

Share Price

Skr435.00

Change (1 day)

+0.00%

52-Week Range

Skr264.40 - Skr447.20

All Time High

Skr447.20